Form 4 for VRCA Verrica Pharmaceuticals Inc.
Accepted 2023-07-24 00:00:00 ET · period of report 2023-07-24 · accession 0001209191-23-043255 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-24 | 2023-07-24 | VRCA | Manning Paul B | Dir, 10% | P - Purchase | $5.02 | +200.0K | 7.85M | +3% | +$1.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-24 | P | A | 200,000 | $5.02 | 7,851,128 | D | — | — | (F1) The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.75 to $5.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F2) Reflects the Reporting Person's contribution of shares into the PBM 2022 Grantor Retained Annuity Trust. This transfer of shares constitutes a change in the form of beneficial ownership and was exempt from reporting. (F3) The shares are held by Mr. Manning jointly with his spouse. |